ArriVent BioPharma, Inc. Common Stock

10-Year Study

AVBP.US · Healthcare · US · Common Stock

Executive Summary: ArriVent BioPharma, Inc. Common Stock has compounded at 15.2% annually over the last 10 years, with a maximum drawdown of 38.4% and an annualized volatility of 115.2%.

1Y CAGR
+43.6%
3Y CAGR
+15.2%
5Y CAGR
+15.2%
10Y CAGR
+15.2%

History & Riski10-year historical performance analysis including CAGR, Max Drawdown, Sharpe & Sortino ratios, annual returns, and rolling volatility — all computed from daily market data.

10-Year Growth of $10,000

Max DrawdownMax DrawdownThe largest peak-to-trough decline in the asset's value over the measurement period.Click for full definition →
38.4%
Sharpe RatioSharpe RatioRisk-adjusted return: how much excess return you earn per unit of total risk (volatility).Click for full definition →
0.49
Sortino RatioSortino RatioLike Sharpe, but only penalizes downside volatility — a more accurate risk measure for asymmetric return distributions.Click for full definition →
0.98
Ann. VolatilityAnnualized VolatilityThe annualized standard deviation of an asset's returns — a measure of how much prices fluctuate.Click for full definition →
48.2%
Best YearBest & Worst YearThe single calendar year with the highest and lowest return in the measured period.Click for full definition →
2026 · +47.2%
Worst YearBest & Worst YearThe single calendar year with the highest and lowest return in the measured period.Click for full definition →
2025 · -24.5%
% Positive Years% Positive YearsThe percentage of calendar years in the measurement period where the asset delivered a positive return.Click for full definition →
50%

Annual Returns

Rolling 12-Month Returns

Rolling 12-Month Annualised Volatility

Historical Drawdowns

Monthly Returns

Monthly Returns Heatmap

YearJanFebMarAprMayJunJulAugSepOctNovDecAnn.
202611.82.10.428.3————————47.2%
20257.1-17.3-21.715.0-0.02.4-10.4-2.0-3.51.522.5-12.3-24.5%
2024—-0.0-17.1-7.517.5-4.418.122.1-12.124.92.1-11.123.6%

Risk X-RayiA 19-factor macroeconomic risk decomposition showing exactly which market forces (equity beta, rates, inflation, credit, commodity, crypto) drive this asset's volatility. Powered by multivariate regression against daily factor returns.

Risk Profile Insight: This asset has an estimated annualized volatility of 115.2%. The dominant macroeconomic risk driver is TIP.US, accounting for 53.2% of variance. Idiosyncratic stock-specific factors contribute 5.2%.

10-Year Historical Price Series (Growth of $10,000)
DateSimulated Value
2024-01-0110000
2024-02-019995.3596287703
2024-03-018287.7030162413
2024-04-017665.893271461717
2024-05-019006.960556844548
2024-06-018607.888631090487
2024-07-0110162.412993039443
2024-08-0112403.712296983758
2024-09-0110904.872389791182
2024-10-0113614.849187935035
2024-11-0113902.552204176334
2024-12-0112361.948955916472
2025-01-0113243.619489559163
2025-02-0110955.916473317864
2025-03-018580.046403712297
2025-04-019865.429234338748
2025-05-019860.788863109048
2025-06-0110102.088167053365
2025-07-019053.364269141532
2025-08-018872.389791183296
2025-09-018561.484918793503
2025-10-018691.415313225058
2025-11-0110645.011600928074
2025-12-019336.426914153131
2026-01-0110436.194895591647
2026-02-0110658.932714617169
2026-03-0110705.336426914153
2026-04-0113740.13921113689
Annual Return Matrix
YearAnnual Return
2025-0.24474474474474472
20260.4716699801192843
Total Factor Risk
1.1523921215448811
VTI.US Exposure
-0.047964314453401616
VEA.US Exposure
-0.05318533294600718
VWO.US Exposure
0.01871969056754271
QQQ.US Exposure
0.1416850208215823
VTV.US Exposure
0.09537421309499258
IJR.US Exposure
-0.042964545295144194
QUAL.US Exposure
-0.035863012412966
SHV.US Exposure
0.0490686272757791
TLT.US Exposure
0.0010574497196447548
LQD.US Exposure
0.00006415369572702072
HYG.US Exposure
0.02211954012212191
GLD.US Exposure
-0.0008323919132185123
USO.US Exposure
-0.0019445722174933461
VNQ.US Exposure
0.183569242790871
BTC-USD.CC Exposure
0.009052920908834956
CPER.US Exposure
-0.0008119200986686503
VIX.INDX Exposure
0.03266845690603739
UUP.US Exposure
0.04531152912712151
TIP.US Exposure
0.5324984027368271
Idiosyncratic Exposure
0.05237684156981714
Value Score
50
Growth Score
50
Profit Score
37.5
Health Score
23.6
Yield Score
0
Moat Score
40

Factor Risk Decomposition

Share of annualised volatility attributable to each macro factor.

Total Est. Vol
115.2%

FundamentalsiCompany financial health metrics: P/E valuation, dividend yield, Piotroski F-Score (9-point profitability signal), Altman Z-Score (bankruptcy risk proxy), and a radar chart across 6 fundamental dimensions. Note: ETFs may show N/A for some metrics.

Fundamental Dimensions

Core Valuation

P/E Ratio (TTM)P/E RatioPrice-to-Earnings ratio — the market price of a stock divided by its earnings per share, a key valuation measure.Click for full definition →N/A
Dividend YieldDividend YieldAnnual dividend paid per share divided by the current share price — expressed as a percentage income return.Click for full definition →0.00%
Market Cap$1.1B
Piotroski F-ScorePiotroski F-ScoreA 9-point scoring system evaluating a company's financial strength across profitability, leverage, and operating efficiency.Click for full definition →
9-point profitability signal
0.0/ 9
Weak
Altman Z-ScoreAltman Z-ScoreA bankruptcy prediction model that combines 5 financial ratios into a single score indicating financial distress risk.Click for full definition →
Bankruptcy risk proxy
1.18
Distress Zone
Income Simulation

Based on $10,000 initial investment.

Total Income Generated
$0
Avg Yield on Cost
0.00%

Momentum & MacroiPrice momentum indicators relative to key technical levels: distance from 50-Day SMA (intermediate trend), 200-Day SMA (long-term trend), 52-Week High (bullish proximity), and Beta (market sensitivity coefficient).

vs 50-Day SMAMoving Averages (SMA)A rolling average of an asset's price over a defined window — used to identify trends and momentum signals.Click for full definition →
+24.6%
Above/below 50-day moving average
vs 200-Day SMAMoving Averages (SMA)A rolling average of an asset's price over a defined window — used to identify trends and momentum signals.Click for full definition →
+39.1%
Above/below 200-day moving average
vs 52-Week High52-Week HighThe highest price an asset reached in the past 52 weeks — a key reference for momentum and valuation context.Click for full definition →
0.0% from high
Distance from 52-week high
BetaBetaA measure of an asset's sensitivity to broad market movements relative to a benchmark (e.g. S&P 500).Click for full definition →
0.86
Market sensitivity coefficient

Frequently Asked Questions & Methodology

Is ArriVent BioPharma, Inc. Common Stock a high-risk investment?

ArriVent BioPharma, Inc. Common Stock (AVBP.US) has an annualized volatility of 115.2% and experienced a maximum drawdown of 38.4% over the last 10 years. Its primary macro risk driver is TIP.US.

What is the 10-year return of AVBP.US?

Over the past 10 years, AVBP.US has generated a Compound Annual Growth Rate (CAGR) of 15.2%. It has had a positive return in 50% of the years measured.

Data Methodology & Trust

The risk and return information on this page is pre-calculated mathematically using daily market data spanning a 10-year period. Fundamentals (such as P/E Ratio, Market Cap, and Dividend Yield) represent trailing averages and may not immediately reflect real-time live market fluctuations. Advanced scoring models like the Piotroski F-Score and Altman Z-Score are proxies applied to publicly available trailing-twelve-month financial statements and may not account for recent off-balance-sheet events, qualitative company shifts, or sector-specific capital structures. Macroeconomic factor exposures are estimated via multivariate regression against standard market indices. This data is provided for quantitative insight and backtesting research, and should not be misconstrued as tailored financial advice.

Run a Full Backtest on ArriVent BioPharma, Inc. Common Stock

stresstest.pro lets you simulate DCA vs Lump Sum, Monte Carlo projections, portfolio optimisation, and more — all in seconds.

Start a Free Backtest